Health-related quality of life and its correlates in Japanese patients with myotonic dystrophy type 1
暂无分享,去创建一个
N. Watanabe | Norio Sugawara | E. Kimura | H. Takada | S. Kon | R. Ono | Makiko Endo | Kaori Odaira | Go Kurauchi | Atsushi Koseki | Momoko Goto | Yumi Sato
[1] F. Mahoney,et al. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 2018, Maryland state medical journal.
[2] T. Heskes,et al. Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial , 2018, The Lancet Neurology.
[3] S. Suwazono,et al. Cognitive impairment and quality of life in patients with myotonic dystrophy type 1 , 2018, Muscle and Nerve.
[4] E. Bonanni,et al. Disruption of sleep-wake continuum in myotonic dystrophy type 1: Beyond conventional sleep staging , 2018, Neuromuscular Disorders.
[5] R. Moxley,et al. Myotonic dystrophy patient preferences in patient‐reported outcome measures , 2018, Muscle & nerve.
[6] C. Heatwole,et al. Prospective measurement of quality of life in myotonic dystrophy type 1 , 2017, Acta neurologica Scandinavica.
[7] R. Kessels,et al. The cognitive profile of myotonic dystrophy type 1: A systematic review and meta-analysis , 2017, Cortex.
[8] V. Rakocevic-Stojanovic,et al. Five‐year study of quality of life in myotonic dystrophy , 2016, Acta neurologica Scandinavica.
[9] G. Bassez,et al. Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification. , 2016, Revue neurologique.
[10] B. Gandek,et al. Standardizing disease-specific quality of life measures across multiple chronic conditions: development and initial evaluation of the QOL Disease Impact Scale (QDIS®) , 2016, Health and Quality of Life Outcomes.
[11] M. Cosottini,et al. Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study , 2016, Orphanet Journal of Rare Diseases.
[12] Bruno Eymard,et al. Prevalence and correlates of apathy in myotonic dystrophy type 1 , 2015, BMC Neurology.
[13] R. Moss‐Morris. Adjusting to chronic illness: time for a unified theory. , 2013, British journal of health psychology.
[14] L. Noreau,et al. Clinical, Psychosocial, and Central Correlates of Quality of Life in Myotonic Dystrophy Type 1 Patients , 2013, European Neurology.
[15] D. Lavrnić,et al. Influence of multisystemic affection on health-related quality of life in patients with myotonic dystrophy type 1 , 2013, Clinical Neurology and Neurosurgery.
[16] Y. Dauvilliers,et al. Daytime Sleepiness and Myotonic Dystrophy , 2013, Current Neurology and Neuroscience Reports.
[17] R. Moxley,et al. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1) , 2012, Neurology.
[18] S. Kyle,et al. A systematic review of quality of life in adults with muscle disease , 2011, Journal of Neurology.
[19] G. Borm,et al. High disease impact of myotonic dystrophy type 2 on physical and mental functioning , 2011, Journal of Neurology.
[20] L. Samuelsson,et al. Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates , 2010, Behavioral and Brain Functions.
[21] K. Harms-Ringdahl,et al. Perceived functioning and disability in adults with myotonic dystrophy type 1: a survey according to the International Classification Of Functioning, Disability and Health. , 2009, Journal of rehabilitation medicine.
[22] Y. Dauvilliers,et al. Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: To lump or split? , 2009, Neuromuscular Disorders.
[23] S. Fukuhara,et al. Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. , 2009, Sleep medicine.
[24] F. Giubilei,et al. Health-related quality of life in myotonic dystrophy type 1 and its relationship with cognitive and emotional functioning. , 2006, Journal of rehabilitation medicine.
[25] M. Zwarts,et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[26] M. Sprangers,et al. Integrating response shift into health-related quality of life research: a theoretical model. , 1999, Social science & medicine.
[27] S. Fukuhara,et al. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. , 1998, Journal of clinical epidemiology.
[28] J E Ware,et al. Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. , 1998, Journal of clinical epidemiology.
[29] R Jouvent,et al. Psychopathological and emotional deficits in myotonic dystrophy , 1998, Journal of neurology, neurosurgery, and psychiatry.
[30] R. Korneluk,et al. Intergenerational stability of the myotonic dystrophy protomutation. , 1993, Human molecular genetics.
[31] J. G. Dijk,et al. Disruption of sleep-wake rhythmicity and daytime sleepiness in myotonic dystrophy , 1993, Journal of the Neurological Sciences.
[32] R. Korneluk,et al. Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy , 1992, Nature Genetics.
[33] David E. Housman,et al. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member , 1992, Cell.
[34] W. Kingston. Myotonic Dystrophy, 2nd Ed. , 1990, Neurology.
[35] M. Duveneck,et al. Depression in myotonic muscular dystrophy. , 1986, Archives of physical medicine and rehabilitation.
[36] R. Brumback,et al. The depression of myotonic dystrophy: response to imipramine. , 1983, Journal of neurology, neurosurgery, and psychiatry.
[37] L. Radloff. The CES-D Scale , 1977 .
[38] H. Mayberg,et al. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. , 1992, The Journal of neuropsychiatry and clinical neurosciences.